Alto Neuroscience (NYSE:ANRO) Trading Up 6.5% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price shot up 6.5% during trading on Tuesday . The stock traded as high as $24.18 and last traded at $24.4190. 31,965 shares traded hands during trading, a decline of 89% from the average daily volume of 288,659 shares. The stock had previously closed at $22.93.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ANRO shares. Wolfe Research initiated coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Finally, JonesTrading lowered their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Price Performance

The stock has a market cap of $877.74 million, a PE ratio of -10.34 and a beta of 1.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The business has a fifty day moving average of $22.76 and a 200 day moving average of $20.08.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Invesco Ltd. bought a new position in Alto Neuroscience during the 1st quarter valued at $67,000. AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience in the 1st quarter worth about $52,000. Marshall Wace LLP raised its stake in shares of Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at about $240,000. Finally, Bridgeway Capital Management LLC lifted its position in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.